Overcoming Challenges with the Adoption of Point-of-Care Testing: From Technology Push and Clinical Needs to Value Propositions.
clinical needs assessment
point-of-care testing
point-of-care tests for STIs
technology adoption
value proposition
Journal
Point of care
ISSN: 1533-029X
Titre abrégé: Point Care
Pays: United States
ID NLM: 101165285
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
29
12
2020
Statut:
ppublish
Résumé
Major technical challenges often prevent developers from producing new point-of-care technologies that deliver the required clinical performance in the intended settings of use. But even when devices meet clinical requirements, they can fail to be adopted and successfully implemented. Adoption barriers occur when decision makers do not understand the "value proposition" of new technologies. Current discussions of value in the context of point-of-care testing focus predominantly on the intended use and performance of the device from the manufacturer's point-of-view. However, the perspective of potential adopters in determining whether new devices provide value is also important, as is the opinion of all stakeholders who will be impacted. Incorporating value concepts into decisions made across the full development-to-adoption continuum can increase the likelihood that point-of-care testing will have the desired impact on health care delivery and patient outcomes. This article discusses how various approaches to technology development impact adoption and compares the characteristics of these approaches to emerging value concepts. It also provides an overview of value initiatives and tools that are being developed to support the evaluation of value propositions. These are presented for a range of technology adoption decision contexts, with particular applicability to point-of-care testing. Expanding the focus of research to address gaps in both the creation and evaluation of value propositions is imperative in order for value concepts to positively influence the adoption of point-of-care testing.
Identifiants
pubmed: 33364914
doi: 10.1097/POC.0000000000000209
pmc: PMC7751984
mid: NIHMS1653606
doi:
Types de publication
Journal Article
Langues
eng
Pagination
77-83Subventions
Organisme : NIBIB NIH HHS
ID : U54 EB007958
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068613
Pays : United States
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Int J Technol Assess Health Care. 2017 Jan;33(1):54-62
pubmed: 28578750
Pharmacoeconomics. 2014 Apr;32(4):345-65
pubmed: 24504851
Health Res Policy Syst. 2015 Apr 28;13:24
pubmed: 25928535
Ann Emerg Med. 2019 Jul;74(1):36-44
pubmed: 30392736
Surgery. 2017 Sep;162(3):471-476
pubmed: 29656954
Sex Health. 2013 Dec;10(6):541-5
pubmed: 24160838
Value Health. 2019 May;22(5):601-606
pubmed: 31104741
Clin Infect Dis. 2020 Apr 15;70(9):1816-1823
pubmed: 31504314
J Hosp Infect. 2012 Jul;81(3):163-8
pubmed: 22633278
EJIFCC. 2018 Jul 11;29(2):129-137
pubmed: 30050396
Value Health. 2018 Feb;21(2):124-130
pubmed: 29477389
Scand J Clin Lab Invest. 2019 Sep;79(5):298-304
pubmed: 31082284
Clin Chem. 2018 Oct;64(10):1439-1452
pubmed: 29884677
BMC Fam Pract. 2019 Jan 10;20(1):8
pubmed: 30630430
PLoS Med. 2017 Jul 7;14(7):e1002344
pubmed: 28686231
Pediatrics. 2016 Jun;137(6):
pubmed: 27207490
Value Health. 2019 Sep;22(9):977-980
pubmed: 31511186
Int J Technol Assess Health Care. 2013 Oct;29(4):353-9
pubmed: 23845404
Clin Chem Lab Med. 2019 May 27;57(6):845-855
pubmed: 30412463
Med Care Res Rev. 2020 Dec;77(6):596-608
pubmed: 30902036
Expert Rev Mol Diagn. 2016;16(4):415-22
pubmed: 26783053
Value Health. 2016 Jan;19(1):1-13
pubmed: 26797229
Eur Endocrinol. 2018 Apr;14(1):24-29
pubmed: 29922348
Implement Sci. 2017 Dec 04;12(1):145
pubmed: 29202772
Value Health. 2019 Nov;22(11):1283-1288
pubmed: 31708065
Value Health. 2018 Apr;21(4):394-397
pubmed: 29680094
Value Health. 2019 Jun;22(6S):S18-S23
pubmed: 31200802
BMC Fam Pract. 2016 Nov 3;17(1):149
pubmed: 27809865
Int J Technol Assess Health Care. 2017 Jan;33(2):323-329
pubmed: 28578735
Point Care. 2012 Jun;11(2):108-113
pubmed: 23935405
BMC Health Serv Res. 2019 Jul 23;19(1):514
pubmed: 31337393
Sex Transm Infect. 2017 Dec;93(S4):S31-S35
pubmed: 28684611
JACC Basic Transl Sci. 2016 Oct 31;1(6):541-547
pubmed: 30167537
Expert Rev Anti Infect Ther. 2014 Jun;12(6):657-72
pubmed: 24484215
Sex Transm Infect. 2014 Mar;90(2):104-11
pubmed: 24273127
PLoS One. 2012;7(10):e47459
pubmed: 23118871
Value Health. 2018 Feb;21(2):119-123
pubmed: 29477388
BMJ Open. 2019 Apr 24;9(4):e025752
pubmed: 31023757
Health Econ Rev. 2017 Dec;7(1):17
pubmed: 28470542
Health Econ. 2014 Apr;23(4):379-83
pubmed: 24590701
Value Health. 2016 Jul-Aug;19(5):577-87
pubmed: 27565275
J Clin Microbiol. 2008 Oct;46(10):3467-9
pubmed: 18685008
Value Health. 2015 Jun;18(4):505-11
pubmed: 26091605
Int J Technol Assess Health Care. 2019 Jan;35(1):50-55
pubmed: 30732667
PLoS One. 2011 Apr 29;6(4):e19263
pubmed: 21559435
Sex Transm Dis. 2018 Nov;45(11):723-727
pubmed: 29771869
Value Health. 2012 Dec;15(8):1172-81
pubmed: 23244821
Clin Infect Dis. 2020 Apr 15;70(9):1824-1825
pubmed: 31504333
Pharmacoeconomics. 2017 Jul;35(7):727-740
pubmed: 28432642
PLoS One. 2010 Nov 30;5(11):e14144
pubmed: 21152386
Sex Health. 2018 Jul;15(4):318-324
pubmed: 29914611
Curr Opin Biomed Eng. 2019 Sep;11:145-148
pubmed: 33178901
BMJ Open. 2017 Sep 1;7(9):e015760
pubmed: 28864692
Value Health. 2019 Jun;22(6S):S12-S17
pubmed: 31200801
Value Health. 2018 Feb;21(2):155-160
pubmed: 29477393
Value Health. 2019 Jan;22(1):13-20
pubmed: 30661627
IEEE J Transl Eng Health Med. 2016 Aug 16;4:2800614
pubmed: 27730014
Point Care. 2012 Jun 1;11(2):126-129
pubmed: 22844231
Value Health. 2019 May;22(5):505-510
pubmed: 31104727
Sex Transm Infect. 2017 Dec;93(S4):S69-S80
pubmed: 29223965
Value Health. 2016 Mar-Apr;19(2):125-37
pubmed: 27021745